This federal Project Grant award of $248,847 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to investigate the role of mitochondrial dysfunction in driving aggressive prostate cancer, particularly among high-risk populations like African American men.
The key objectives are to: 1) Identify mitochondrial DNA (mtDNA) alterations associated with aggressive prostate cancer and assess their clinical relevance for disparities; 2) Use metformin as a proof-of-concept to establish precision strategies targeting mitochondrial dysfunction; and 3) Leverage mouse models to understand how mitochondrial metabolic rewiring contributes to aggressive disease and identify novel mitochondrial biomarkers to improve precision interception. This work will be carried out by the primary awardee, Rutgers The State University of New Jersey, over the 3-year project period from February 2025 to January 2028. The findings from this research are expected to provide the conceptual basis, preliminary data, and experimental tools for the principal investigator to pursue further independent funding and advance their career in precision oncology approaches to high-risk prostate cancer.
Generated 3/25/25, 5:00 AM